ACRV
Acrivon Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.74
+4.19%Oct 29, 2026, 12:00 UTC
Acrivon Therapeutics, Inc. announced that early Phase 1/2 results for its ACR-2316 inhibitor will be presented at the 38th EORTC-NCI-AACR Symposium on November 20, 2026.
Source: